XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)
 3 Months Ended
Apr. 02, 2023
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earning Per Share
The following presents the detailed calculation of EPS:
 Three Months Ended
(MILLIONS)April 2,
2023		April 3,
2022
EPS Numerator––Basic
Income from continuing operations attributable to Pfizer Inc. common shareholders$5,542 $7,872 
Discontinued operations––net of tax1 (9)
Net income attributable to Pfizer Inc. common shareholders$5,543 $7,864 
EPS Numerator––Diluted  
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions$5,542 $7,872 
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions1 (9)
Net income attributable to Pfizer Inc. common shareholders and assumed conversions$5,543 $7,864 
EPS Denominator  
Weighted-average number of common shares outstanding––Basic5,634 5,617 
Common-share equivalents93 141 
Weighted-average number of common shares outstanding––Diluted5,727 5,758 
Anti-dilutive common stock equivalents(a)
2 — 
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.